Abeona Therapeutics Says ZEVASKYN Launch Is Back on Track, Eyes Profitability in 2026 [Yahoo! Finance]
Abeona Therapeutics Inc. (ABEO)
Last abeona therapeutics inc. earnings: 3/16 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.abeonatherapeutics.com
Company Research
Source: Yahoo! Finance
Abeona has qualified four treatment centers, is operating at about 6 manufacturing slots/month with a plan to ramp to ~10 in H2 and to activate 5–7 centers in 2026, and expects to reach profitability in 2026 if it treats north of three patients per month (management says that level may be reached by Q2). The commercial target is roughly 750 moderate-to-severe RDEB patients (about 1,500 treatment opportunities assuming ~2 treatments per patient), and the company aims to shorten the current 4–5 month order-to-treatment process to an ideal ~90 days with a 25-day manufacturing window. Interested in Abeona Therapeutics Inc.? Here are five stocks we like better. Abeona Therapeutics (NASDAQ:ABEO) executives said the commercial launch of ZEVASKYN is gaining momentum after an early manufacturing-related delay, outlining progress on treatment center activation, patient onboarding, and capacity expansion during remarks at the Leerink Partners Global Healthcare Conference. Launch progres
Show less
Read more
Impact Snapshot
Event Time:
ABEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABEO alerts
High impacting Abeona Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ABEO
News
- Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB [Seeking Alpha]Seeking Alpha
- Abeona Therapeutics (ABEO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point [Seeking Alpha]Seeking Alpha
- Abeona Therapeutics (ABEO) was given a new $17.00 price target by Stifel Nicolaus.MarketBeat
- Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ... [Yahoo! Finance]Yahoo! Finance
ABEO
Earnings
- 3/17/26 - Beat
ABEO
Sec Filings
- 3/20/26 - Form 8-K
- 3/17/26 - Form 10-K
- 3/17/26 - Form 8-K
- ABEO's page on the SEC website